ALTERNATIVE研究更新:拉帕替尼联合曲妥珠单抗双靶联合芳香化酶抑制剂治疗HR阳性/HER2阳性转移性乳腺癌
ALTERNATIVE研究是一项III期随机研究,评估拉帕替尼联合曲妥珠单抗双靶联合芳香化酶抑制剂(AI)用于绝经后HER2阳性/HR阳性转移性乳腺癌患者的疗效与安全性。该方案为需要避免化疗的患者提供了有效且安全的替代选择。
要点
- 双靶联合AI较单靶联合AI显著延长PFS,HR为0.62。
- 主要不良事件为腹泻、皮疹、恶心和甲沟炎,多为1-2级。
- 双靶联合AI提供免化疗的治疗选择,安全性可控。
核心结论
- 拉帕替尼联合曲妥珠单抗联合芳香化酶抑制剂较曲妥珠单抗联合芳香化酶抑制剂在HER2阳性/HR阳性转移性乳腺癌中显示优越的无进展生存获益。
- 该联合方案为这一患者人群提供了有效且安全的免化疗替代治疗方案。
研究设计与样本
- 主要终点为研究者评估的无进展生存期(PFS),比较拉帕替尼+曲妥珠单抗+AI组与曲妥珠单抗+AI组。
主要发现
- 拉帕替尼+曲妥珠单抗+AI组在总缓解率、临床获益率和总生存期方面也显示优势。
- 常见不良事件(≥15%)在拉帕替尼+曲妥珠单抗+AI组、曲妥珠单抗+AI组和拉帕替尼+AI组分别为腹泻(69%、9%、51%)、皮疹(36%、2%、28%)、恶心(22%、9%、22%)和甲沟炎(30%、0%、15%),多为1级或2级。
- 严重不良事件在三组间相似,导致停药的不良事件在拉帕替尼+曲妥珠单抗+AI组较低。
关键数值与推荐
- 常见不良事件(≥15%)包括腹泻(69%、9%、51%)、皮疹(36%、2%、28%)、恶心(22%、9%、22%)和甲沟炎(30%、0%、15%),对应三组分别为拉帕替尼+曲妥珠单抗+AI、曲妥珠单抗+AI和拉帕替尼+AI。
临床怎么用
- 对于既往接受过内分泌治疗和曲妥珠单抗联合化疗的绝经后HER2阳性/HR阳性转移性乳腺癌患者,可考虑拉帕替尼联合曲妥珠单抗联合芳香化酶抑制剂作为免化疗方案。
- 治疗期间需监测腹泻、皮疹、恶心和甲沟炎等不良事件,多数为1-2级,严重不良事件需及时处理。
局限性
- 本文为更新结果,部分次要疗效分析因编程错误进行了数值修正,但不改变主要结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. This updated article reflects minor numerical corrections in some secondary efficacy analyses that resulted from programming errors and that do not change the major conclusions of the study. METHODS: Patients were randomly assigned (1:1:1) to receive lapatinib (LAP) plus TRAS plus AI, TRAS plus AI, or LAP plus AI. Patients for whom chemotherapy was intended were excluded. The primary end point was progression-free survival (PFS; investigator assessed) with LAP plus TRAS plus AI versus TRAS plus AI. Secondary end points were PFS (comparison of other arms), overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and safety. RESULTS: Three hundred fifty-five patients were included in this analysis: LAP plus TRAS plus AI (n = 120), TRAS plus AI (n = 117), and LAP plus AI (n = 118). Baseline characteristics were balanced. The study met its primary end point; superior PFS was observed with LAP plus TRAS plus AI versus TRAS plus AI (median PFS, 11 v 5.6 months; hazard ratio, 0.62 [95% CI, 0.45 to 0.88]; P = .0063). A consistent PFS benefit was observed in predefined subgroups. ORR, CBR, and OS also favored LAP plus TRAS plus AI. The median PFS with LAP plus AI versus TRAS plus AI was 8.3 versus 5.6 months (hazard ratio, 0.85 [95% CI, 0.62 to 1.17]; P = .3159). Common adverse events (AEs; ≥ 15%) with LAP plus TRAS plus AI, TRAS plus AI, and LAP plus AI were diarrhea (69%, 9%, and 51%, respectively), rash (36%, 2%, and 28%, respectively), nausea (22%, 9%, and 22%, respectively), and paronychia (30%, 0%, and 15%, respectively), mostly grade 1 or 2. Serious AEs were reported similarly across the 3 groups, and AEs leading to discontinuation were lower with LAP plus TRAS plus AI. CONCLUSION: Dual HER2 blockade with LAP plus TRAS plus AI showed superior PFS benefit versus TRAS plus AI in patients with HER2-positive/HR-positive MBC. This combination offers an effective and safe chemotherapy-sparing alternative treatment regimen for this patient population.
引用
- Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol. 2020. PMID: 32822287. doi:10.1200/JCO.20.01894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。